Last reviewed 2026-06-01 · How we verify

Decaserpin (METHOSERPIDINE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Decaserpin (generic name: METHOSERPIDINE) is a methoserpidine drug. It is currently in Phase 2 development.

Decaserpin works by interacting with an unknown target to produce its effects.

Decaserpin is a small molecule with the synonyms 10-MD, (-)-10-METHOXYDESERPIDINE, 10-METHOXYDESERPIDINE, DEASERPYL, DECASERPIL, and DECASERPIN.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METHOSERPIDINE
Drug class	methoserpidine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, we don't know exactly how decaserpin works, but it's thought to affect the body's response to certain stimuli. This can lead to changes in how the body functions, but more research is needed to understand the details. Essentially, decaserpin is a mystery in terms of its mechanism of action.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Decaserpin CI brief — competitive landscape report
Decaserpin updates RSS · CI watch RSS

Frequently asked questions about Decaserpin

What is Decaserpin?

Decaserpin (METHOSERPIDINE) is a methoserpidine drug.

How does Decaserpin work?

Decaserpin works by interacting with an unknown target to produce its effects.

What is the generic name of Decaserpin?

METHOSERPIDINE is the generic (nonproprietary) name of Decaserpin.

What drug class is Decaserpin in?

Decaserpin belongs to the methoserpidine class. See all methoserpidine drugs at /class/methoserpidine.

What development phase is Decaserpin in?

Decaserpin is in Phase 2.

Drug class: All methoserpidine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing